Singapore has one of the highest prevalence of high myopia in the world, particularly among the younger working population. As these individuals grow older, the burden of myopia-related blindness will increase exponentially. The High Myopia Clinic at SNEC was set up to meet this emerging healthcare need. It is a specialised clinic for patients with high myopia and/or pathologic myopia.
The goal of the High Myopia Clinic is to identify patients who are at the greatest risk of permanent vision loss from pathologic myopia, and to guide research on novel treatments for the prevention of sight threatening complications.
On a typical visit to the high myopia clinic, the patient undergoes vision and eye pressure measurements similar to any other SNEC clinic. This is followed by measurements of the eye length and a series of advanced, non-invasive imaging of the optic nerve, retina and choroid to diagnose pathologic myopia-related complications like glaucoma, myopic choroidal neovascularisation, myopic retinoschisis and myopic macular degeneration.
These tests include swept source optical coherence tomography that allows high-resolution 3D imaging of the macula and the optic nerve, and optical coherence tomographic angiography for non-invasive imaging of the retinal and choroidal blood flow.
Patients may also undergo biomechanical testing to measure the stiffness of the posterior eye wall with ultrasonography to assess the risk of further eye elongation and worsening myopia. They will then be examined by one of our subspecialty experts who focuses specifically on the diseases and needs of patients with high myopia. Those with treatable conditions can be identified early and receive treatment in a timely manner to preserve or improve vision. Stable patients will be monitored on an annual basis for progression.
By caring for the large number of highly myopic patients, coupled with our sophisticated imaging techniques, we can determine which patients are at the highest risk of permanent vision loss from pathologic myopia and make advancements in the way we treat sight-threatening complications of high myopia.
Subscribe to our mailing list to get the updates to your inbox